FFO
ACAD icon

Fortitude Family Office’s Acadia Pharmaceuticals ACAD Stock Holding History

Fortitude Family Office’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
399
+368
+1,187% +$8.1K ﹤0.01% 765
2026
Q1 		$690 Buy
31
+10
+48% +$239 ﹤0.01% 1614
2025
Q4 		$561 Sell
21
-11
-34% -$263 ﹤0.01% 1664
2025
Q3 		$683 Buy
32
+22
+220% +$520 ﹤0.01% 1691
2025
Q2 		$216 Buy
+10
New +$186 ﹤0.01% 1954

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fortitude Family Office's ACAD Position: Q2 2026 in Review

Fortitude Family Office increased its Acadia Pharmaceuticals (ACAD) stake by 1,187% in Q2 2026, buying an estimated $8.1K and bringing the position to 399 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Fortitude Family Office first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Fortitude Family Office held 399 shares of Acadia Pharmaceuticals worth $10.1K as of Q2 2026.
  • Fortitude Family Office bought 368 Acadia Pharmaceuticals shares in Q2 2026, an estimated $8.1K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #765 holding.
  • Fortitude Family Office first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.